Monitoring Agency Report for the quarter ended 30 June 2025 in relation to the InitialPublic Offer (IPO) of the Company.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences filed the Monitoring Agency Report from CRISIL Ratings for the quarter ended June 30, 2025, tracking use of its December 2024 IPO proceeds. The IPO raised Rs 30,426.20 million total, comprising a Rs 9,500 million fresh issue and Rs 20,926.20 million offer-for-sale, leaving Rs 9,098.84 million in net fresh-issue proceeds. Of this, Rs 7,200 million earmarked for repaying borrowings was fully utilized by March 31, 2025. During the latest quarter, Rs 165.72 million was deployed toward general corporate purposes (purchase of equipment and machinery), taking cumulative utilization to Rs 8,135.81 million. The remaining Rs 963.03 million is parked in SBI fixed deposits and the public offer account, earning about 7.7% interest. CRISIL noted no deviations from stated objects and no delays in implementation.
This is a routine compliance filing that confirms IPO funds are being deployed as disclosed, with no red flags on misuse or delays. Neutral to mildly positive for shareholders, as disciplined utilization and idle funds earning interest suggest steady execution of the stated plan.